According to a story from medwirenews.com, a post-hoc analysis from a recent clinical trial has revealed that treatment with filgotinib can result in improvements in structural lesions detected by MRI…
According to biotechnology Gilead Sciences, the FDA rejected a new drug application (NDA) for filgotinib. The drug, designed to treat patients with moderate to severe rheumatoid arthritis (RA), is known…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
